Coherus Biosciences | CHRS - Equity Capital And Reserves

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $87.77M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Akebia Therapeutics USD 41.59M 12.37M Sep/2025
ALKERMES USD 1.73B 108.85M Sep/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 458.89M 6.03M Sep/2025
Amgen USD 8.66B 961M Dec/2025
Baxter International USD 6.13B 1.11B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Coherus Biosciences USD 87.77M 32.05M Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Fujifilm JPY 3.72T 230.16B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Myriad Genetics USD 372.8M 15.3M Sep/2025
Pacira USD 727.21M 30.55M Sep/2025
Perrigo USD 4.45B 25.8M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xencor USD 625.32M 4.96M Sep/2025
Zoetis USD 3.33B 2.07B Dec/2025